Inhibition of nuclear entry of HPV16 pseudovirus-packaged DNA by an anti-HPV16 L2 neutralizing antibody (Q39671503)

13 September 2017

Inhibition of nuclear entry of HPV16 pseudovirus-packaged DNA by an anti-HPV16 L2 neutralizing antibody (English)

1 reference

13 September 2017

1 reference

Yoshiyuki Ishii

1

1 reference

13 September 2017

Keiko Tanaka

2

1 reference

13 September 2017

Kazunari Kondo

3

1 reference

13 September 2017

Takamasa Takeuchi

4

1 reference

13 September 2017

Seiichiro Mori

5

1 reference

13 September 2017

Tadahito Kanda

6

1 reference

13 September 2017

language of work or name

English

0 references

publication date

4 August 2010

1 reference

13 September 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

Virology

1 reference

13 September 2017

406

1 reference

13 September 2017

2

1 reference

13 September 2017

181-188

1 reference

Target cell cyclophilins facilitate human papillomavirus type 16 infection

13 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Interaction of tSNARE syntaxin 18 with the papillomavirus minor capsid protein mediates infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Efficient intracellular assembly of papillomaviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Overlapping and independent structural roles for human papillomavirus type 16 L2 conserved cysteines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Papillomaviruses infect cells via a clathrin-dependent pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Interactions between papillomavirus L1 and L2 capsid proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Human papillomavirus infection requires cell surface heparan sulfate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Mechanisms regulating expression of the HPV 31 L1 and L2 capsid proteins and pseudovirion entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Mutational analysis of human papillomavirus type 16 major capsid protein L1: the cysteines affecting the intermolecular bonding and structure of L1-capsids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Thiol-reactive reagents inhibits intracellular trafficking of human papillomavirus type 16 pseudovirions by binding to cysteine residues of major capsid protein L1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Establishment of human papillomavirus infection requires cell cycle progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Caveolin-1-dependent infectious entry of human papillomavirus type 31 in human keratinocytes proceeds to the endosomal pathway for pH-dependent uncoating

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Clathrin- and caveolin-independent entry of human papillomavirus type 16--involvement of tetraspanin-enriched microdomains (TEMs)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Early phase in the infection of cultured cells with papillomavirus virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

Papillomaviruses and cancer: from basic studies to clinical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.07.019

10.1016/J.VIROL.2010.07.019

7 January 2021

Identifiers

DOI

1 reference

13 September 2017

1 reference